Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression

Publication date: Available online 29 January 2019Source: SteroidsAuthor(s): Konstantina Kalyvianaki, Athanasios A. Panagiotopoulos, Panagiotis Malamos, Eleni Moustou, Maria Tzardi, Efstathios N. Stathopoulos, Georgios S. Ioannidis, Kostas Marias, George Notas, Panayiotis A. Theodoropoulos, Elias Castanas, Marilena KampaAbstractAccumulating evidence during the last decades revealed that androgens exert membrane-initiated actions leading to the modulation of significant cellular processes, important for cancer cell growth and metastasis (including prostate and breast), that involve signaling via specific kinases. Collectively, many nonclassical, cell surface-initiated androgen actions are mediated by novel membrane androgen receptors (mARs), unrelated to nuclear androgen receptors. Recently, our group identified the G protein coupled oxo-eicosanoid receptor 1 (OXER1) (a receptor of the arachidonic acid metabolite, 5-oxoeicosatetraenoic acid, 5-oxoETE) as a novel mAR involved in the rapid effects of androgens. However, two other membrane proteins, G protein-coupled receptor family C group 6 member A (GPRC6A) and zinc transporter member 9 (ZIP9) have also been portrayed as mARs, related to the extranuclear action of androgens. In the present work, we present a comparative study of in silico pharmacology, gene expression and immunocytochemical data of the three receptors in various prostate and breast cancer cell lines. Furthermore, we analyzed the immunohistochemical expression ...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research